Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer's Three-Pronged Oncology Strategy Includes Expanding Ibrance, Xtandi, Developing Blockbuster Combos

May 22 2018

• By Brenda Sandburg

Digital illustration of Cancer cell in colour background

Related Content

Keeping Track: Vitaros Reenters The Wilderness, Remoxy Gives It A Fourth Try, And Two Novel Approvals

Feb 19 2018

Keeping Track Of Good News For AstraZeneca, Pfizer, Promius, And Sunovion

Apr 08 2018

Pfizer's Mylotarg Likely To Get New Orphan, Biologics Exclusivities

Sep 08 2017

Pfizer Poised To PROSPER From Xtandi In Expanded Indication

Sep 14 2017

The Most Successful Oncology Launches Of A Decade

Feb 28 2018

'We Jumped' At Opportunity To Take On Pfizer's CAR-T Program, Allogene's Chang Says

Apr 04 2018

Related Companies

Pfizer Inc.

AstraZeneca PLC

Eli Lilly and Company

Merck KGaA

Astellas Pharma, Inc.

Kite Pharma, Inc.

Allogene Therapeutics Inc.

Cellectis SA

Medivation, Inc.

Bristol Myers Squibb Company

Merck & Co., Inc.

Additional Topics

Business Strategies Research & Development Commercial Cancer BioPharmaceutical

More from Anticancer

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window